- Home
- ENPH vs BLTE Comparison
ENPH vs BLTE Comparison
Compare ENPH & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENPH | BLTE |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.1B |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ENPH | BLTE |
|---|---|---|
| Price | $43.87 | $164.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 25 | 8 |
| Target Price | $43.48 | ★ $181.14 |
| AVG Volume (30 Days) | ★ 4.6M | 152.7K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.00 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $1,472,985,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.00 | $218.41 |
| P/E Ratio | $33.02 | ★ N/A |
| Revenue Growth | ★ 10.72 | N/A |
| 52 Week Low | $25.78 | $49.00 |
| 52 Week High | $64.47 | $200.00 |
Technical Indicators
Market Signals| Indicator | ENPH | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 51.71 | 40.45 |
| Support Level | $43.00 | $148.78 |
| Resistance Level | $46.94 | $165.64 |
| Average True Range (ATR) | 2.38 | 8.54 |
| MACD | -0.43 | -2.36 |
| Stochastic Oscillator | 38.68 | 1.63 |
Price Performance
Historical ComparisonAbout ENPH Enphase Energy Inc.
Enphase Energy is a global energy technology company. It delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Enphase derives a majority of revenue from the United States.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.